Terlipressin facilities transport of septic patients treated with norepinephrine

Israel Medical Association Journal

Volumn 8, Issue 10, 2006, Pages 691-693

  Klein, Moti ^a   Weksler, Natan ^a   Borer, Avraham ^a   Koyfman, Leonid ^a   Kesslin, Jerome ^b,c   Gurman, Garbriel M ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Critically ill patient transport; Norepinephrine; Septic shock; Terlipressin

Indexed keywords

LONG ACTING DRUG; NORADRENALIN; TERLIPRESSIN; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; LYPRESSIN; VASOCONSTRICTOR AGENT;

ACROCYANOSIS; ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEALTH CARE FACILITY; HEMODYNAMICS; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; INTESTINE ISCHEMIA; LIMB ISCHEMIA; MALE; MORTALITY; PATIENT TRANSPORT; RISK ASSESSMENT; SEPTIC SHOCK; SKIN INJURY; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; BLOOD PRESSURE; DRUG EFFECT; METHODOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYSINE VASOPRESSIN; MALE; MIDDLE AGED; NOREPINEPHRINE; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; TRANSPORTATION OF PATIENTS; VASOCONSTRICTOR AGENTS;

EID: 33750731639     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
2. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002;359:1209-10.
3. Gurman G. Computerized data storage and statistics for intensive care units. Harefuah 1987;113:103-5 (Hebrew).
4. Lovell MA, Mudaliar MY, Klineberg PL. Intrahospital transport of critically ill patients: complications and difficulties. Anesth Intensive Care 2001;29:400-5.
5. Noguera I, Medina P, Segarra G, et al. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery. Br J Pharmacol 1997;122:431-8.
6. Brierre S, Kumari R, Deboisblanc BP. The endocrine system during sepsis. Am J Med Sci 2004;328:238-47.
7. Chen P. Vasopressin: new uses in critical care. Am J Med Sci 2002; 324:146-54.
8. Bernadich C, Bandi JC, Melin P, Bosch J. Effects of F-180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension. Hepatology 1998;27(2):351-6.
9. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 1990;16:307-14.
10. Lebrec D. Review article: future indications for terlipressin therapy. Aliment Pharmacol Ther 2004;20(Suppl 3):65-8.
11. Nevens F. Review article: a critical comparison of drug therapies in currently used therapeutic strategies for variceal haemorrhage. Aliment Pharmacol Ther 2004;20(Suppl 3):18-23.
12. Morelli A, Tritapepe L, Rocco M, et al. Terlipressin versus norepinephrine to counteract anesthesia-induced hypotension in patients treated with renin-angiotensin system inhibitors: effects on systemic and regional hemodynamics. Anesthesiology 2005;102:12-19.
13. Hansen EF, Strandberg C, Hojgaard L, et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J Hepatol 1999;30:503-10.
14. Scharte M, Meyer J, Van Aken H, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep. Crit Care Med 2001;29:1756-60.
15. Jolley DH, De Keulenaer BL, Potter A, Stephens DP. Terlipressin infusion in catecholamine-resistant shock. Anesth Intensive Care 2003;31:560-4.
16. Leone M, Albanese J, Delmas A, Chaabane W, Garnier F, Martin C. Terlipressin in catecholamine-resistant septic shock patients. Shock 2004;22:314-19.
17. Matok I, Vard A, Efrati O, et al. Terlipressin as rescue therapy for intractable hypotension due to septic shock in children. Shock 2005;23:305-10.
18. Peters MJ, Booth RA, Petros AJ. Terlipressin bolus induces systemic vasoconstriction in septic shock. Pediatr Crit Care Med 2004;5:112-15.
19. Rodriguez-Nunez A, Fernandez-Sanmartin M, Martinon-Torres F, Gonzalez-Alonso N, Martinon-Sanchez JM. Terlipressin for catecholamine-resistant septic shock in children. Intensive Care Med 2004;30:477-80.
20. Rodriguez-Nunez A, Lopez-Herce J, Gil-Anton J, Hernandez A, Rey C. Rescue treatment with terlipressin in children with refractory septic shock: a clinical study. Crit Care 2006;31:R20.
21. Fellahi JL, Benard P, Daccache G, Mourgeon E, Gerard JL. Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?. Ann Fr Anesth Reanim 2003;22:631-4.
22. Westphal M, Ertmer C, Van Aken H, Bone HG. Terlipressin in patients with septic shock: friend or foe? Intensive Care Med 2004;30:992.
23. Asfar P, Pierrot M, Veal N, et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003;31:215-20.
24. Morelli A, Rocco M, Conti G, et al. Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004;30:597-604.
25. Warren J, Fromm RE, Jr., Orr RA, Rotello LC, Horst HM. Guidelines for the inter- and intrahospital transport of critically ill patients. Crit Care Med 2004;32:256-62.